344951-08-2

Basic information

• Product Name: Aziridine, 1-[(2-nitrophenyl)sulfonyl]-
• CAS NO: 344951-08-2
• Molecular Formula: C8H8N2O4S
• Molecular Weight: 228.229
• Mol File: 344951-08-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Aziridine, 1-[(2-nitrophenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Aziridine, 1-[(2-nitrophenyl)sulfonyl]-(344951-08-2)
• EPA Substance Registry System: Aziridine, 1-[(2-nitrophenyl)sulfonyl]-(344951-08-2)

Safety Data

• Hazardous Substances Data: 344951-08-2(Hazardous Substances Data)

Upstream product

• 151-56-4 ethyleneimine 
• 54090-41-4 2-nitro-p-toluenesulfonyl chloride 
• 18226-11-4 N-(2-hydroxy-ethyl)-2-nitro-benzenesulfonamide 
• 1972-28-7 diethylazodicarboxylate 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 496921-42-7 methanesulfonic acid 2-(2-nitrobenzenesulfonylamino) ethyl ester 

Downstream Products

• 1361843-53-9 N-(2-nitrophenyl)sulfonyl-2-(2-(E)-buten-1-yloxy)ethylamine 
• 1361844-09-8 4-[(2-nitrophenyl)sulfonyl]-3-vinylmorpholine 
• 1370451-36-7 1-[2-(2-nitrophenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 
• 1370451-42-5 1-[2-(2-aminophenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 344951-14-0 (7-{(diethoxy-phosphoryl)-[2-(2-nitro-benzenesulfonylamino)-ethyl]-amino}-heptyl)-carbamic acid tert-butyl ester 
• 344951-18-4 [7-(2-bromo-acetylamino)-heptyl]-[2-(2-nitro-benzenesulfonylamino)-ethyl]-phosphoramidic acid diethyl ester 
• 344951-20-8 [4-(2-Nitro-benzenesulfonyl)-6-oxo-1,4,7-triaza-cyclotetradec-1-yl]-phosphonic acid diethyl ester 
• 344951-16-2 (7-amino-heptyl)-[2-(2-nitro-benzenesulfonylamino)-ethyl]-phosphoramidic acid diethyl ester 
• 344951-12-8 {7-[2-(2-nitro-benzenesulfonylamino)-ethylamino]-heptyl}-carbamic acid tert-butyl ester 
• 344951-10-6 N-[2-(7-amino-heptylamino)-ethyl]-2-nitro-benzenesulfonamide 

Relevant articles and documents

Carbazole compounds and therapeutic uses of the compounds

Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Development of hypoxia-sensitive Gd3+-based MRI contrast agents

Hypoxia occurs in various diseases, including cancer, ischemia, and acute and chronic vascular diseases. Here we describe the design and synthesis of the first hypoxia-sensitive MRI contrast agents, SAGds. SAGds showed a pH-dependent r1 relaxivity change associated with intramolecular chelation of the nitrogen atom of the sulfonamide moiety to the Gd3+ center. There was a correlation between the pKa of the r1 relaxivity change and the sum of the Hammett σ constants of substituents on the aromatic ring. Among the synthesized compounds, 4NO22MeOSAGd was selectively reduced to the amine by rat liver microsomes under hypoxic conditions, resulting in a 1.8-fold increment of the r1 relaxivity owing to the change in pKa of the arylsulfonamide moiety. This enhancement of the r 1 relaxivity could be clearly detected in T1-weighted MR images. Thus, 4NO22MeOSAGd is a 'smart' MRI contrast agent for the detection of hypoxia under physiological conditions.

Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone

Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology. The compounds have the formulae: where n is 1 to 200, B is a protect